Organogenesis Holdings Inc
NASDAQ:ORGO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.28
4.49
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Organogenesis Holdings Inc
Organogenesis Holdings Inc
Total Assets
Organogenesis Holdings Inc
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Organogenesis Holdings Inc
NASDAQ:ORGO
|
Total Assets
$446.3m
|
CAGR 3-Years
6%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Assets
$143.4B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
19%
|
CAGR 10-Years
18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Assets
$54.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Assets
$90.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Assets
$22.2B
|
CAGR 3-Years
21%
|
CAGR 5-Years
24%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Assets
$37.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
22%
|
CAGR 10-Years
26%
|
|
Organogenesis Holdings Inc
Glance View
Organogenesis Holdings, Inc. is a regenerative medical company. The company is headquartered in Canton, Massachusetts and currently employs 950 full-time employees. The company went IPO on 2016-12-02. Its solutions address comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease, and smoking. The wound care products include Apligraf for the treatment of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs); Dermagraft for the treatment of diabetic foot ulcer (DFU); PuraPly AM and PuraPly XT as antimicrobial barriers for variety of wound types; and the Affinity and NuShield wound coverings to address a variety of wound sizes and types. Its surgical and sports medicine product includes ReNu for in-office knee osteoarthritis treatment; NuCel for bony fusion in the lumbar spine; NuShield and Affinity barrier products for surgical application in targeted soft tissue repairs; and PuraPly AM for management of open wounds in the surgical setting.
See Also
What is Organogenesis Holdings Inc's Total Assets?
Total Assets
446.3m
USD
Based on the financial report for Sep 30, 2024, Organogenesis Holdings Inc's Total Assets amounts to 446.3m USD.
What is Organogenesis Holdings Inc's Total Assets growth rate?
Total Assets CAGR 5Y
21%
Over the last year, the Total Assets growth was -4%. The average annual Total Assets growth rates for Organogenesis Holdings Inc have been 6% over the past three years , 21% over the past five years .
You don't have any saved screeners yet
